The Eli Lilly's antibody-drug reduces COVID-19 in nursing homes in the latest study


Eli Lilly’s antibody-drug was found to significantly reduce the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, the company said Thursday.

The drug is being evaluated as part of a Phase 3 trial involving 965 participants that were conducted in part by the National Institute of Allergy and Infectious Diseases and the COVID-19 Prevention Network...


See the whole story on Fox Business right here,

0 comments